Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US clearance for PharmaNetics' heparin test panel:

This article was originally published in Clinica

Executive Summary

PharmaNetics has received US FDA 510(k) clearance for its Heparin Management Panel and Accent system, which adds two new test cards, the Heparin Titration Test and the Protamine Response Test, as well as new hardware to the company's current Heparin Management Test, which runs on its Thrombolytic Assessment System (TAS). The Accent hardware automatically calculates information to manage anticoagulation in patients during cardiopulmonary bypass procedures. Bayer Diagnostics, which markets TAS as Rapidpoint Coag, will market the new product as Rapidpoint ACCENT. Raleigh, North Carolina-based PharmaNetics is the holding company of Cardiovascular Diagnostics.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT073079

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel